In nearly 5,000 patients who regained weight after sleeve gastrectomy, conversion to gastric bypass produced 11% greater total body weight loss over 3 years compared to GLP-1 receptor agonists like semaglutide or tirzepatide.
11% Greater Weight Loss with SurgeryIn 4,901 patients after failed sleeve gastrectomy, conversion to RYGB outperformed GLP-1 receptor agonists by 11% total body weight loss at 3 years after adjusting for baseline characteristics
What the researchers found
Among 4,901 patients (3,004 conversion RYGB, 1,897 GLP-1 RA) with prior sleeve gastrectomy, pre-intervention weights were identical between groups (242.8 vs. 242.3 lbs, p=0.993). In multivariate analysis adjusting for sex, baseline BMI, age, and race, conversion to RYGB was associated with 11% greater percentage total body weight loss compared to GLP-1 RA treatment at 3 years. Both groups showed similar improvements in HbA1c at all time points (p>0.05). The cRYGB group had higher baseline HbA1c (6.19 vs. 5.85, p significant).
Why it matters
As GLP-1 drugs become widely available, more patients are considering them as an alternative to revision surgery after failed bariatric procedures. This is one of the largest studies directly comparing these two approaches, providing data that helps patients and surgeons make informed decisions. The 11% weight loss difference is clinically meaningful but must be weighed against the risks and costs of a second surgery.
How the study worked
This was a multicenter academic retrospective study including adult patients (≥18 years) who previously had sleeve gastrectomy and were subsequently treated with weekly injectable semaglutide or tirzepatide, or underwent conversion to Roux-en-Y gastric bypass. Patients converted for GERD, those with BMI ≤35 on GLP-1 RA, or with pre-operative GLP-1 RA use were excluded. Weight and HbA1c were assessed from 3 months to 3 years. T-test, ANOVA, chi-squared, and multivariable linear regression analyses were used.
What this study cannot tell us
This is a retrospective study, making it susceptible to selection bias — patients offered GLP-1 drugs vs. revision surgery may differ in ways not captured by baseline characteristics. GLP-1 RA adherence and duration of use were not tracked. The study did not assess quality of life, complications, or patient satisfaction. Semaglutide and tirzepatide were analyzed together despite different mechanisms.
How to read the evidence
This is a large, multicenter retrospective study with nearly 5,000 patients and multivariable regression analysis. While the sample size is impressive, the retrospective design limits causal conclusions due to potential selection bias and unmeasured confounders.
When this study was published
Published in 2025, this study uses current-generation GLP-1 agonists (semaglutide and tirzepatide) and provides timely data for the ongoing debate about medical vs. surgical obesity management.
The bigger picture
This study directly addresses one of the most debated questions in obesity medicine: can GLP-1 peptide drugs replace revision bariatric surgery? While the answer here favors surgery for weight loss, the similar diabetes improvements and lower risk profile of GLP-1 drugs mean the choice isn't straightforward. As even more potent GLP-1 agonists enter the market, this comparison may shift — making ongoing head-to-head studies essential.
Questions still open
- Would higher-dose semaglutide or tirzepatide narrow the weight loss gap with revision surgery?
- What are the comparative complication rates and quality of life outcomes between these two approaches?
- Could sequential treatment — GLP-1 RA followed by revision surgery for non-responders — optimize outcomes?
Common questions
If my sleeve gastrectomy didn't work, should I take GLP-1 drugs or have another surgery?
Do GLP-1 drugs work as well as revision surgery for diabetes?
Read the original research
Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study.
Surgical endoscopy, 39(9), 6155-6162
Citation
Brown, Avery; Sergent, Helena; Vu, Alexander Hien; Liu, Helen; Fisher, Jason; Somoza, Eduardo; Mei, Tony; Lipman, Jeffrey; Park, Julia; Chui, Patricia; Saunders, John; Kurian, Marina; Tchokouani, Loic; Orandi, Babak; Ferzli, George; Chhabra, Karan; Ren-Fielding, Christine; Parikh, Manish; Jenkins, Megan. (2025). Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study.. Surgical endoscopy, 39(9), 6155-6162. https://doi.org/10.1007/s00464-025-11942-8